Product details

The pharmaceutical industry has reason to be convinced of the seriousness with which transgressions of corporate compliance legislation are dealt with. This case examines how a large multi-national pharmaceutical company, SmithKline Beecham (SB), has successfully gone about developing a corporate compliance programme. The case begins by looking at the legislative environment which makes such a programme necessary, noting the key role of the US Federal Sentencing Guidelines and goes on to outline some of the ethical issues facing pharmaceutical companies. It then charts the process by which SB implemented its corporate compliance programme, focusing on its company-wide Code of Conduct and the specific training on it given by lawyers in one of its divisions.